title: Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.
abstract: Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from transplantation, off immunosuppression for ⩾30 days and free of GvHD. Thirty-four patients with similar disease characteristics and fulfilling the same selection criteria served as controls. Median follow-up among aDLT recipients was 7.2 years. Ten patients (22%) relapsed inspite of aDLT, as compared with 53% in the control group. Induction of GvHD was the main complication. However, non-relapse mortality was low with patients dying from infection (n=2), severe chronic GvHD (n=1) and secondary malignancy (n=2). At the time of analysis, 31/46 aDLT recipients were alive in CR at a median of 5.7 years after first aDLT. Overall survival at 7 years after transplant was 67% as compared with 31% in the control group (P<0.001). In conclusion, aDLT is safe, when given in escalating doses to a well predefined group of patients. Long-term survival can be achieved.
authors.affiliation: Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.|Department of Medicine II, University Hospital, Frankfurt, Germany.
authors.forename: Z
authors.initials: Z
authors.lastname: Jedlickova
authors.affiliation: Department of Hematology and Oncology, Klinikum Augsburg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Schmid
authors.affiliation: Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
authors.forename: C
authors.identifier: http://orcid.org/0000-0001-7025-1735
authors.initials: C
authors.lastname: Koenecke
authors.affiliation: Department of Medicine I, Clinical Center, Bremen Mitte, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Hertenstein
authors.affiliation: Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Baurmann
authors.affiliation: Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schwerdtfeger
authors.affiliation: Department of Medicine III, Grosshadern, University Hospital of Munich (Ludwig Maximilians University), Munich, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Tischer
authors.affiliation: Department of Medicine III, University Hospital rechts der Isar, Munich, Germany.
authors.forename: H-J
authors.initials: HJ
authors.lastname: Kolb
authors.affiliation: Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.
authors.forename: M
authors.identifier: http://orcid.org/0000-0001-8564-4662
authors.initials: M
authors.lastname: Schleuning
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease; D006801:Humans; D007239:Infections; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000401:mortality / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000379:methods*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary; D012008:Recurrence; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D055815:Young Adult